Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)
April 27, 2022 07:14 AM EDTUpdated 09:45 AM
R&D
China
Pharma

No­var­tis records an­oth­er tislelizum­ab win en route to bring­ing BeiGene's PD-1 to FDA's doors

Kyle LaHucik

Senior Reporter

The lat­est crop of da­ta is out for No­var­tis and BeiGene’s tislelizum­ab as the part­ners look to pad their case for the PD-1 in­hibitor’s ex­pan­sion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times